Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021
ABSTRACT Background This study evaluates shifts in oral glucose‐lowering drug prescription patterns and the adoption of sodium‐glucose cotransporter 2 inhibitors (SGLT2is) in South Korea. Methods A cross‐sectional and retrospective cohort analysis of the Korean National Health Insurance database (20...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-02-01
|
| Series: | Journal of Diabetes Investigation |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/jdi.14363 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832575034737033216 |
|---|---|
| author | Kyoung Hwa Ha Soyoung Shin EunJi Na Dae Jung Kim |
| author_facet | Kyoung Hwa Ha Soyoung Shin EunJi Na Dae Jung Kim |
| author_sort | Kyoung Hwa Ha |
| collection | DOAJ |
| description | ABSTRACT Background This study evaluates shifts in oral glucose‐lowering drug prescription patterns and the adoption of sodium‐glucose cotransporter 2 inhibitors (SGLT2is) in South Korea. Methods A cross‐sectional and retrospective cohort analysis of the Korean National Health Insurance database (2015–2021) assessed the prescription patterns of oral glucose‐lowering drugs by therapy level, SGLT2i prescriptions by cardiovascular‐renal disease (CVRD) status, and the mean duration for SGLT2i therapy initiation and intensification. Results From 2015 to 2021, the number of individuals prescribed oral glucose‐lowering drugs across all regimen levels increased. However, the proportion of individuals receiving monotherapy or dual combination therapy decreased by 9.2 percentage points, whereas the proportion prescribed triple or more combination therapy increased. SGLT2i prescriptions increased from 2.5% in 2015 to 13.9% in 2021, marking an 11.4 percentage point growth. This trend was consistent among individuals with and without CVRD, with the most significant increase observed in individuals with heart failure—from 2.2% in 2015 to 16.6%. The mean time to SGLT2i initiation post‐diagnosis was shortened from 249 days in 2015 to 158 days in 2019. Conclusions The adoption of SGLT2i therapy was on the rise, especially among individuals with heart failure, accompanied by a notable decrease in time to treatment initiation. Despite these positive trends, the overall use of SGLT2i among individuals with CVRD remained limited. |
| format | Article |
| id | doaj-art-a86b71b7cf63488caab93a8d68b4b3df |
| institution | Kabale University |
| issn | 2040-1116 2040-1124 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Investigation |
| spelling | doaj-art-a86b71b7cf63488caab93a8d68b4b3df2025-02-01T10:02:01ZengWileyJournal of Diabetes Investigation2040-11162040-11242025-02-0116221522410.1111/jdi.14363Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021Kyoung Hwa Ha0Soyoung Shin1EunJi Na2Dae Jung Kim3Department of Endocrinology and Metabolism Ajou University School of Medicine Suwon KoreaMedical Affairs Boehringer‐Ingelheim Korea Seoul KoreaMedical Affairs Boehringer‐Ingelheim Korea Seoul KoreaDepartment of Endocrinology and Metabolism Ajou University School of Medicine Suwon KoreaABSTRACT Background This study evaluates shifts in oral glucose‐lowering drug prescription patterns and the adoption of sodium‐glucose cotransporter 2 inhibitors (SGLT2is) in South Korea. Methods A cross‐sectional and retrospective cohort analysis of the Korean National Health Insurance database (2015–2021) assessed the prescription patterns of oral glucose‐lowering drugs by therapy level, SGLT2i prescriptions by cardiovascular‐renal disease (CVRD) status, and the mean duration for SGLT2i therapy initiation and intensification. Results From 2015 to 2021, the number of individuals prescribed oral glucose‐lowering drugs across all regimen levels increased. However, the proportion of individuals receiving monotherapy or dual combination therapy decreased by 9.2 percentage points, whereas the proportion prescribed triple or more combination therapy increased. SGLT2i prescriptions increased from 2.5% in 2015 to 13.9% in 2021, marking an 11.4 percentage point growth. This trend was consistent among individuals with and without CVRD, with the most significant increase observed in individuals with heart failure—from 2.2% in 2015 to 16.6%. The mean time to SGLT2i initiation post‐diagnosis was shortened from 249 days in 2015 to 158 days in 2019. Conclusions The adoption of SGLT2i therapy was on the rise, especially among individuals with heart failure, accompanied by a notable decrease in time to treatment initiation. Despite these positive trends, the overall use of SGLT2i among individuals with CVRD remained limited.https://doi.org/10.1111/jdi.14363Cardiovascular diseasesKidney diseaseSodium‐glucose transporter 2 inhibitors |
| spellingShingle | Kyoung Hwa Ha Soyoung Shin EunJi Na Dae Jung Kim Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021 Journal of Diabetes Investigation Cardiovascular diseases Kidney disease Sodium‐glucose transporter 2 inhibitors |
| title | Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021 |
| title_full | Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021 |
| title_fullStr | Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021 |
| title_full_unstemmed | Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021 |
| title_short | Trends in prescribing sodium‐glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular‐renal disease in South Korea, 2015–2021 |
| title_sort | trends in prescribing sodium glucose cotransporter 2 inhibitors for individuals with type 2 diabetes with and without cardiovascular renal disease in south korea 2015 2021 |
| topic | Cardiovascular diseases Kidney disease Sodium‐glucose transporter 2 inhibitors |
| url | https://doi.org/10.1111/jdi.14363 |
| work_keys_str_mv | AT kyounghwaha trendsinprescribingsodiumglucosecotransporter2inhibitorsforindividualswithtype2diabeteswithandwithoutcardiovascularrenaldiseaseinsouthkorea20152021 AT soyoungshin trendsinprescribingsodiumglucosecotransporter2inhibitorsforindividualswithtype2diabeteswithandwithoutcardiovascularrenaldiseaseinsouthkorea20152021 AT eunjina trendsinprescribingsodiumglucosecotransporter2inhibitorsforindividualswithtype2diabeteswithandwithoutcardiovascularrenaldiseaseinsouthkorea20152021 AT daejungkim trendsinprescribingsodiumglucosecotransporter2inhibitorsforindividualswithtype2diabeteswithandwithoutcardiovascularrenaldiseaseinsouthkorea20152021 |